‘Precise Bio’ announced a new partnership with ‘Carl Zeiss Meditec’ (Zeiss) whereby the two companies will collaborate on creating bioprinted corneal implants. Zeiss sought to invest in Precise Bio once again, based on the success of the collaboration between the two companies back in 2020 when they created lens implants.
According to Precise Bio’s CEO, Aryeh Batt, the corneal implants are intended to “address unmet needs in the field of ophthalmology,” showing that the companies are primarily motivated by the needs of patients and consumers around the world.
The details of the partnership include Zeiss investing in purchasing equity in Precise Bio, as well as Zeiss securing the exclusive rights to commercialize the corneal implants in the global market once the product has been approved.
Image Credit: Precise Bio
